2024-10-12 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**1. Performance vs. S&P 500:**

Eli Lilly and Co (LLY) is a pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical products.  LLY has outperformed the S&P 500 significantly.  The cumulative return for LLY is 874.69%, compared to 134.11% for the S&P 500 (VOO), resulting in a **740.58%** difference. This places LLY at the **91.91%** percentile in terms of relative performance against the S&P 500 over the historical period analyzed. 

**2. Recent Price Movements:**

* **Closing Price:** 908.57
* **5-day Moving Average:** 905.52
* **20-day Moving Average:** 905.80
* **60-day Moving Average:** 893.59

The recent price movement indicates that LLY is trading slightly above its 5-day and 20-day moving averages, suggesting potential for continued upward momentum. However, the 60-day moving average is below the current price, potentially suggesting a correction or consolidation period in the near future. 

**3. Technical Indicators:**

* **RSI:** 44.53 - This value suggests that the stock is neither overbought nor oversold, indicating potential for further price movement in either direction.
* **PPO:** 0.13 - A positive PPO value suggests a potential for price increases, but it's important to note that it's a relatively small value, suggesting that the momentum may not be strong.
* **Delta_Previous_Relative_Divergence:** -4.63 - The negative value suggests a short-term bearish trend, indicating that the recent relative divergence is decreasing. 
* **Expected Return:** 3.82% - This represents a potential for a 3.82% return on investment over a 5-year period, exceeding the expected return of the S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue | 
|---|---|---|
| 2024-08-08 | 3.29 | $11.30 B |
| 2024-04-30 | 2.49 | $8.77 B |
| 2023-11-02 | -0.06 | $9.50 B |
| 2023-08-08 | 1.96 | $8.31 B |
| 2024-08-08 | 1.96 | $8.31 B |

The most recent earnings report for the quarter ending August 2024 shows that Eli Lilly exceeded analysts' expectations, with EPS of $3.29 compared to an estimated $2.92. Revenue also surpassed expectations, reaching $11.30 billion against an estimated $10.85 billion. This positive performance reflects the company's strong product portfolio and robust demand for its medications, especially its diabetes drugs, including Mounjaro. 

Looking forward, analysts remain optimistic about LLY's growth prospects, citing continued demand for its existing products and promising pipeline of new drugs, including its Alzheimer's treatment, donanemab, which is currently in phase 3 trials.  

**5. News and Recent Issues:**

Recent market sentiment surrounding LLY is generally positive. Analysts are impressed with the company's strong earnings performance and its promising pipeline of new drugs. [FINBOLD](https://finbold.com/eli-lilly-and-company-lly-stock-analysis-outlook-and-forecast/) reports that several analysts have upgraded LLY to a "buy" rating, citing the company's "robust financial performance" and "growth potential." 

One key factor influencing LLY's recent performance is the success of its diabetes drug, Mounjaro. The drug has gained immense popularity, contributing significantly to LLY's revenue growth. However, the company is also facing increasing competition in the diabetes market, with other pharmaceutical companies also developing similar drugs.

**6. Overall Analysis:**

Eli Lilly and Co. (LLY) is a strong performer with a promising future.  Despite its recent short-term bearish trend, its robust financial performance, promising product pipeline, and positive market sentiment suggest that LLY is well-positioned for continued growth in the long term. The stock's strong performance against the S&P 500 further strengthens its attractiveness as a potential investment opportunity. 

**7. Recommendations:**

Given the company's consistent performance, strong earnings, and promising future prospects, LLY appears to be a solid investment for long-term investors seeking growth and potential outperformance against the market. However, it's crucial to monitor the company's future earnings reports and the market's reaction to its new drug developments to make informed investment decisions.  

**Disclaimer:** This analysis is for informational purposes only and should not be considered as investment advice. It is crucial to conduct thorough research and consult with a financial professional before making any investment decisions.
